Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

FORM vs Hers

FORM and Hers both sell semaglutide and tirzepatide; this is how their prices, coverage and records differ.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed
FORM logo

FORM

7.5
★★★★☆3.8/5

Best for: starting below a standard dose, with microdose tiers

Visit FORM →
VS
Hers logo

Hers

6.6
★★★☆☆3.3/5

Best for: coverage in all 50 states, which most sellers will not confirm

Visit Hers →

If you are choosing between FORM and Hers, price alone will not settle it. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. FORM leads our six-part score, 7.5 to 6.6. One of the two has an FDA warning letter on record, covered below.

FORM vs Hers price

FORM and Hers start at the same figure, $199 a month, so the entry price does not separate them. Look at what each price covers and at the per-drug prices below.

Drug by drug: Semaglutide is cheaper at Hers ($199 a month vs $215 a month); tirzepatide is cheaper at FORM ($199 a month vs $299 a month).

Medications and formats

Both sell semaglutide and tirzepatide.

On format, FORM prices compounded injections, while Hers prices compounded injections and brand-name pens.

If you want the FDA-approved brand rather than a compounded version, Hers is the only one of the two with a brand-name price.

Where each one treats patients

FORM does not publish where it ships, and Hers lists 50 states.

Pricing

FORM

Standard injectable, once-weekly, provider-titrated, monthly auto-refillCompounded
$299/mo
semaglutide

$299 per month.

Standard injectable, provider-titrated, monthly auto-refillCompounded
$399/mo
tirzepatide

$399 per month.

Oral ODT (dissolving tablet), monthly auto-refillCompounded
$215/mo
semaglutide

$215 per month.

Oral ODT (dissolving tablet), monthly auto-refillCompounded
$299/mo
tirzepatide

$299 per month.

Microdose starter program, lower-strength injectable, monthlyCompounded
$199/mo
tirzepatide

$199 per month.

Oral tablet — required monthly membership (subscription; Wegovy® medication billed separately via NovoCare Pharmacy)Brand-name
$95/mo
semaglutide

A $95 monthly membership that covers access and consults. The Wegovy itself is billed separately through NovoCare, and FORM does not publish that cost.

Injectable — required monthly membership (subscription; Zepbound® medication billed separately via LillyDirect)Brand-name
$95/mo
tirzepatide

A $95 monthly membership that covers access and consults. The Zepbound itself is billed separately through LillyDirect, and FORM does not publish that cost.

Hers

StartingCompounded
$199/mo
semaglutide
StartingBrand-name
$299/mo
tirzepatide

Brand Zepbound from $299/mo medication-only; requires Hers Weight Loss Membership ($149/mo)

What each price covers

Both prices cover the medication itself.

FORM's price also covers the clinician visit and shipping, which Hers does not claim.

FORM is silent on lab work and coaching.

Hers is silent on shipping and lab work.

FORM

Covered by the monthly price

Medication

In the price

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

Not stated

Hers

Covered by the monthly price

Medication

In the price

Clinician visits

Charged on top

Shipping

Not stated

Lab work

Not stated

Coaching

Charged on top

Where each one scores higher

Overall, FORM scores 7.5 and Hers 6.6 out of 10.

FORM is stronger on value (6.6 vs 3.0), trust & safety (6.5 vs 5.5) and support (7.0 vs 3.0).

Hers is stronger on accessibility (10.0 vs 5.0).

Effectiveness and user experience are within half a point.

How we score

FORM

7.5/10

Overall

Hers

6.6/10

Value25%

6.6A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

6.5A
vs
B
5.5

Accessibility10%

5.0A
vs
B
10.0

Support10%

7.0A
vs
B
3.0

FDA warning letters

The FDA sent Hers a warning letter dated September 9, 2025 (letter 716825), and it is still open.

FORM has no FDA warning letter on record with us.

Features & Coverage

FeatureFORMHers
Starting Price$199/mo$199/mo
Features✓8 features2 features
States AvailableNot disclosed50
Compounded✓ Yes✓ Yes
Brand Name✓ Yes✓ Yes
FSA/HSA Accepted——
FDA Warning Letters✓None1 letter

About FORM

$299/month is the opening rate on compounded semaglutide, $399/month on compounded tirzepatide, with microdose tirzepatide at lower strength going for $199/month; dissolving oral tablets exist as well. Reaching FDA-approved Zepbound or Wegovy means a membership of $95/month instead. Las Vegas is the base for FORM by GBY, which writes through the provider network at Övie Health Group and sells longevity, peptide and hair treatments too. Cancel whenever; nothing binds you long term.

Read our full FORM review →

About Hers

Hers is the women-focused telehealth brand from Hims and Hers. It sells compounded semaglutide on a 6-month plan.

Read our full Hers review →

Pros & Cons

FORM

What we like

  • Tirzepatide costs $199 a month, 20% below the $250 median for compounded tirzepatide across the sellers we compare
  • Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • The monthly price includes the medication, clinician visits and shipping
  • We found no FDA warning letters issued to FORM

Watch-outs

  • Semaglutide costs $215 a month, 16% above the $185 median for compounded semaglutide across the sellers we compare
  • Confirm it serves your state before you start the intake
  • Ask which pharmacy fills the prescription before you pay, so you can check its license
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Hers

What we like

  • Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • The monthly price includes the medication
  • Serves all 50 states

Watch-outs

  • Not included in the monthly price: clinician visits, coaching
  • Ask which pharmacy fills the prescription before you pay, so you can check its license
  • The FDA has issued Hers a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
  • Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality

Our Verdict

Winner: FORM

FORM wins this one, 7.5 to 6.6, above all for starting below a standard dose, with microdose tiers. Hers fits better if coverage in all 50 states, which most sellers will not confirm is your priority.

Choose FORM if…

You want starting below a standard dose, with microdose tiers and an opening price near $199 a month.

Choose Hers if…

You want coverage in all 50 states, which most sellers will not confirm and an opening price near $199 a month.

Ready to start? GLP-1 providers we have vetted

Telehealth providers, vetted by us, prescribing GLP-1 online.

Vetted by our editors · no insurance required

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.1

DudeMeds

Compounded semaglutide at $175/month

7.8

Oak

Semaglutide at $119/month, 37% below the typical price

9.4

Trimi Health

Knowing which pharmacy fills the vial: it names VialsRx

FORM vs Hers: FAQ

Neither on the entry price: FORM and Hers both start at about $199 a month. The difference is in what the price includes.
Yes, both sell semaglutide and tirzepatide.
FORM does not publish where it ships; Hers lists 50 states. Confirm your state before paying.
Both include the medication itself. Only FORM includes the clinician visit and shipping.
FORM has none. Hers has an open FDA warning letter from September 9, 2025.
No. Neither FORM nor Hers pays us anything.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.